NEL ASA - Another 56% Downmove?At the last sell-off of NEL ASA shares in May/June 2019, the share went south by 56% in 16 days.
Will the pattern be repeated?
Mixed feelingsStocks don't have feelings, neither should you!
21 MA close to crossing above 50 MA for a buying signal
For the Bull: Buying Zone is at 175-180, Stop below trendline, target 200 Fib 0.618 - 215 Fib 0.786
For the Bear: Break of triangle, scaling in on lower highs, target 143
American cancer vaccine patent boost $PCIB.OL over falling wedgePCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines
Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines.
Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses. The combination of cytokines with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines. The now granted US patent gives broad coverage for the combination of various cytokines with the fimaVacc technology.
There are many vaccines under development utilising cytokines to elicit immune responses. The US patent granted today is important for PCI Biotech’s development strategy, as it supplements our ability to generate an internal future vaccine pipeline, in addition to bringing value for the fimaVacc technology in partnering efforts, said Per Walday, CEO of PCI Biotech.
As part of PCI Biotech’s strategy for applying the PCI-technology for therapeutic cancer vaccines, several global patent applications were filed in 2013 and 2014. Today’s granted US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets.
Press release direct URL:
pcibiotech.no
BerGenBio SMA50/200 golden cross tests breakout upon new dataABOUT BERGENBIO
OSL:BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
www.bergenbio.com
www.nordnet.no
Trinity Delta Analysis:
www.trinitydelta.org
Idex Bio long I think we are having a retest of descending triangel and having a IH&S and getting to target 2.2kr.
EQUINOR (EQNR) | Important Signs For Further Growth!Hi,
Equinor ASA , an energy company, explores for, produces, transports, refines and markets petroleum and petroleum-derived products, and other forms of energy in Norway and internationally.
Fundamental pros:
1. Trading below its fair value.
2. Good PE and PEG ratio.
3. Earnings are forecasted to grow.
4. A lot of insider buying.
Technical pros:
The correction, which started at the end of 2018, has started to show some positive signs for further growth.
1. The price has made a breakout from the down-trendline aka counter-trendline. Counter-trendlines breakouts are a pretty powerful tool to follow, especially when we have a really strong starting platform as Equinor has it at the moment.
2. Actually, the price made a breakout a couple of weeks ago and it has already retest it and again, it got a rejection upwards - the trendline which worked previously as resistance becomes support.
3. The trendline starts to work as support and there are also Weekly EMA 200 and Monthly EMA 50 which also should act as support levels.
So, we have a pretty solid support level under the current price which is very good considering the breakthrough the counter-trendline.
To show that mentioned "strong starting platform", we have to dig into the Monthly timeframe:
The price got a pretty amazing rejection from a super-strong price level, it stays between ~150-160. A lot of criteria matched almost perfectly (strong support, AB=CD, Channel projection, Fibonacci golden ratio, EMA) and the rejection formed the strongest candlestick pattern ever lived (massive hype :D) - Monthly timeframe "Morning Star" has formed around the strong area!
It depends on your investment horizon but the good entry should stay between the current price, 173, to 160 (in case it makes a tiny correction) but as said previously - luckily we have strong support just below the current price. The first target is around the psychological number 200 which should offer us about 17-20 percent profit.
Do your own research and if this matching with mine then you are ready to go!
Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You!
Best regards,
Vaido
LERØY SEAFOOD (LSG) | Strong Fundamentally & Technically!Hi,
Lerøy Seafood Group produces, processes, markets, and distributes fresh, frozen, and smoked seafood products in Norway.
It shows pretty good value numbers, it is way undervalued, insiders (CEO) have bought the stock recently (actually yesterday) and etc.
Fundamentally, Lerøy Seafood looks quite good and most importantly, technically as well. There is a perfect area where you can invest or reinvest to Lerøy Seafood, the area consists of:
1) Weekly EMA200
2) Monthly EMA50
3) The round number 50
4) Channel projection
5) 2x AB=CD
6) Fibonacci Extensions
7) Fibonacci retracement 38%, pulled from all-time low to all-time high.
8) The trendline since 2012, historically, it is worked perfectly as support
9) 2016 high
They all should work as support levels, adding these criteria together gives us a strong support area between 48 - 52.5 , which is also technically a good area to buy Lerøy Seafood.
The first target stays around 60 which is approximately +20%.
Do your own research and if this matching with mine then you are ready to go!
Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You!
Best regards,
Vaido
PCI Biotech $PCIB.OL top 10 hot nordic stocks @veckansaffarer
www.va.se
finansavisen.no
PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities.
The company is applying PCI to three distinct anticancer paradigms:
• fimaCHEM – enhancement of chemotherapeutics for localised treatment of cancer
• fimaVACC – enhanced T-cell induction for therapeutic vaccination
• fimaNAc – nucleic acid therapeutics delivery
The company’s lead fimaCHEM programme consists of a pivotal clinical study with registration intent of Amphinex® in bile duct cancer, an orphan indication with a high-unmet need and without approved products. Clinical proof-of-concept has been achieved in the fimaVACC programme, which applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines. The fimaNAc programme utilises the triggered endosomal release to provide effective intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising class of therapeutics.
Snapshot / observation, climbBrokers Clarksons Platou covers Bonheur (17 Des), and sets objective at NOK 285.
I have suggested both average support and resistance levels in red and blue, and the green upwards trend is self explaining. Holding medium sized position waiting for the (presumptive) January effect.
If the objective is sound and realistic, there should still be plenty time to get aboard.
Bakkafrost, at the top of everything?Bakkafrost looks to be closing to the top of everything, IF previous pattern repeats itself. From just half a year ago Bakkafrost could be bought at around 440 NOK followed by a steady rise to a current 640 NOK. This is a staggering 50% increase in just half a year.
That alone is not the only factor Bakkafrost has against a further rise. We also see that if the Impulse Elliot Waves repeats itself we are close to an A,B,C elliot correction. Or even an A,B,C,D correction. But time will show.
Also Bakkafrost is getting very close to the top of the parallel channel its been impulsing in for close to a year now. If it breaks the channel, thats another case. But I find that unlikely but still possible. So basing it on previous Elliot Waves. We see that impulse wave 1,2,3,4 and 5 was completed. Then the Elliot A,B to C was completed. Immediately after that Bakkafrost continued into a new set of impulse waves, 1,2,3,4 and the fifth close to completing.
Still some more room for a further rise, but again, if the pattern repeats itself, we are likely to soon see the correction in Bakkafrost. I am short
BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimismBerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
www.trinitydelta.org
Twitter:
twitter.com
Investor Relations:
www.bergenbio.com
Telenor nearing buy zone Telenor is currently in a bearish trend, but it's nearing the area where one should look to buy.
We have two significant horisontal supports. The first @ 156.75, and the second at 150.45.
The logic game plan for me, is to place equal bids at the two levels. Making the potential average cost 153.6.
TP 1: 180
(TP 2: 190)
breaking out of pattern?NAS can get compensation from Boeing in 2019, will the stock break out of it falling pattern?
Kongsberg Gruppen trend change, entry 136.1 We've had some positive price development lately, and it looks like the trend is turning bullish.
Golden cross MA50 above MA200 of course adds to our case.
Current resistance is at 142.5....Interested in an entry @ 136.1 marked by the yellow line.
ENTRA en route to price discovery. Blackrock on board Entra hitting new all time highs, here's a possible way to ride the trend at a 6% risk, setting stops below the wick at the last weekly candle.
Blackrock purchased stocks in Entra worth roughly $11m last week.
Aker Solutions.. High risk high reward This consolidation will eventually end, and take a direction.
The obvious play here is to buy here at the lower end of the consolidation. If this breaks out to the upside it can provide solid returns.
Yara bet x 338As we can see from the 1hr here, price bounced off support at 338 at decent volume. This indicates a switch in momentum to the north.
I see resistance at 370 as the target price. But be aware that 200MA will probably provide some resistance first, since it has been well respected in this downtrend.
NB: Entry, SL & TP is calculated from 338, price is now trading at 446.xx
Twin peaks or blue book dream?Any thoughts on this scenario? would P1 and P2 qualify as double peak (supposedly a bullish formation), and is it in your opinion consistent with the later emerging upward trend (double channel)?
As I understand it, a prerequisite for a bullish development is the high traded volume at Peak2 (bottom).
Any opinions and contributions much appreciated!
